权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Innovative Droplet Lenses for NextGen Light Sensors of Biomarkers of Inflammation

用于炎症生物标志物下一代光传感器的创新液滴透镜

基本信息

批准号：
10113067
负责人：
TIMOTHY M SWAGER
金额：
$ 24.84万
依托单位：
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-04-01 至 2024-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10113067
关键词：
Acute-Phase Proteins Address Adoptive Cell Transfers Aftercare Antibodies Binding Biological Markers Blood Blood Tests C-reactive protein CAR T cell therapy Cancerous Cause of Death Cells Cellular Phone Cessation of life Chronic Clinical Collection Communicable Diseases Complex Coronavirus Data Detection Development Devices Disease Outbreaks Dyes Equipment Event Fluorocarbons Future Goals Health Personnel Heart Home Hospitals Hydrocarbons Immune response Immune system Immunotherapy Individual Inflammation Inflammatory Laboratories Lead Light Liquid substance Malignant Neoplasms Malignant neoplasm of lung Measurement Microscope Monitor Morbidity - disease rate Morphology Neurologic Deficit Optics Organ Patient Monitoring Patients Physicians Physiological Positioning Attribute Prognostic Marker Proteins Reaction Reporting Risk Factors Serum Severities Skin Surface Symptoms Technology Test Result Testing Time Toxic effect Training Water Whole Blood Work base cancer prevention cancer therapy cytokine cytokine release syndrome efficacy testing experience flu home test immune checkpoint blockade immune-related adverse events immunoreaction innovation lens light intensity liquid biopsy novel point of care protein biomarkers response sensor sensor technology side effect standard of care treatment optimization

项目摘要

Project Summary/Abstract While the efficacy of immunotherapy can be staggering, a major side effect is that there can be an ensuing excessively robust immune response, which can lead to organ damage, neurological deficits, and even death. In the case of CAR T-cell therapy, it is estimated that between ~20 to 40% of patients experience cytokine release syndrome (CRS). Given its potential severity, it is critical to monitor patients after treatment so that steps can be taken to treat CRS before excessive organ damage. While daily blood tests for a biomarker of inflammation (C-reactive protein; CRP) are effectively performed in the hospital for the first week after treatment, continued testing is not consistent, despite the fact that onset can occur weeks after and even months after treatment. What is needed is a point of care device to monitor established biomarkers of inflammation. We are in a position to take a bold step in sensor development to address this need. We have developed novel sensors that exploit biphasic droplets that act as a multitude of micron scale lenses to reflect and refract light. Complex multi-liquid droplets with antibody functionalized surfaces can change morphology upon binding to analytes, providing strong directional optical changes in response to molecular interactions. Specifically, molecular interactions can impact transmitted light (Type 1 sensors) and reflected light (Type 2 sensors). Such changes in light intensity and direction can be sensed with a smartphone, avoiding the need for expensive and cumbersome equipment and ultimately enabling connections between people and their health care providers. Our overriding goal is to develop Type 1 and Type 2 sensors to detect biomarkers of inflammation at physiologically relevant levels in whole blood or serum. We also propose to test the efficacy of integrated emissive/adsorptive dyes as a means for achieving multiplexing. Specific Aim 1 is to reveal the efficacy of Type 1 sensors for detecting CRP. Specific Aim 2 is to determine the efficacy of Type 2 sensors of reflected light for sensing CRP. Specific Aim 3 is to develop multiplexing capacity. Having a POC sensor will not only be useful for monitoring established biomarkers of inflammation, but it will also give rise to unprecedented depth of longitudinal data. As such, the proposed sensors will open doors to future studies aimed at leveraging detailed temporal response data to better predict immune-related adverse events. The proposed “NextGen” POC sensors offer the potential for exquisite sensitivity, quantitative data, and data in real-time, raising the possibility for droplet sensors to have a broad impact on cancer therapy and prevention.

项目总结/文摘